ERBB2 and breast carcinoma: The MDA-MB-231 human breast cancer cell line is Her2-negative/unamplified but a constitutive over-expression of Her2 in this cell line by genetic engineering produces a derivative cell line (231-H2N) regarded as clinically relevant [17].